Amgen Inc., of Thousand Oaks, Calif., and its subsidiary Onyx Pharmaceuticals Inc. submitted a supplemental new drug application (sNDA) to the FDA and a marketing authorization application (MAA) to the EMA seeking approval to market the proteasome inhibitor Kyprolis (carfilzomib) for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.